PACTR202403843973020
Recruiting
Phase 3
High Dose Dexamethasone versus Prednisone as First Line Therapy in Newly diagnosed Immune Thrombocytopenic Purpura in Children
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Haematological Disorders
- Sponsor
- faculty of medicine of tanta university
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Children aged 1–18 years with newly diagnosed primary ITP before starting any treatment having platelet count \< 30,000 /µ
Exclusion Criteria
- •1\-Patients with secondary ITP including leukemia, drugs, lupus erythematous, hepatitis C, anti\-phospholipid syndrome.
- •2\-Ptaients with ITP who received any treatment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
To compare the effect of 2 drugs namely Prednisolone and Dexamethasone while treating newly diagnosed ITP and to see if there is any correlation with T regulatory cell levelsHealth Condition 1: D693- Immune thrombocytopenic purpuraCTRI/2019/08/020501DrDebranjani Chattopadhyay
Recruiting
Phase 3
Comparing the high-dose dexamethasone effect versus prednisolone in treatment of immune thrombocytopenic purpura patientsIRCT20211111053039N1Oroumia University of Medical Sciences36
Not yet recruiting
Phase 1
Analgesia Comparison between Dexamethasone and Dexmedetomidine used as adjuvants to Bupivacaine in Transversus Abdominis Plane (TAP) block after Lower Segment Caesarean SectioHealth Condition 1: O882- Obstetric thromboembolismCTRI/2019/10/021624Armed forces medical college Pune
Completed
Phase 3
Comparison of the effect of dexamethasone with prednisolone in controlling asthma attacksIRCT20201005048939N1Islamic Azad University120
Recruiting
Phase 4
A clinical trial to study the effects of two drugs,Methylprednisolone and Dexamethasone in patients with Systemic Lupus ErythematosusHealth Condition 1: M321- Systemic lupus erythematosus withorgan or system involvementCTRI/2023/11/059463Dr Anirudh Maslekar